natgillin/translations-raw huggingface dataset:
adjusting said fluid to a pH value of above 7. 
- < osiguravanje da navedena tekućina početno ima pH vrijednost iznad 7.
Machine intended for manufacturing Y-shaped muselets for bottles of effervescent drinks, comprising: means for twisting of one end of a first wire over an overlap region situated approximately in a middle of a second wire, the wires forming part of a same first plane and being oriented therein so as to form an approximate first right angle between a non-twisted end of the first wire and one of free ends of the second wire, and to form a second angle of approximately 135° between the free ends of the second wire; 
- sredstvo za uvijanje jednog kraja prve žice (1) preko područja (20), koje se nalazi otprilike u sredini druge žice (2), gdje žice čine dio iste prve ravnine i tamo su tako da orijentirane čine približno pravi kut A između neuvijenog kraja prve žice i jednog od slobodnih krajeva druge žice, te da čine kut B od otprilike 135" između slobodnih krajeva druge žice;
The method, use or agent according to any one of the preceding claims, wherein the thyroid disorder is selected from the group consisting of hypothyroidism, hyperthyroidism, Graves' disease, autoimmune thyroiditis, and a combination thereof. 
Uporaba prema bilo kojem od zahtjeva 17 i 19 do 28, naznačena time da je poremećaj štitnjače odabran iz skupine koju čine hipotireoza, hipertireoza, Gravesova bolest, autoimuni tiroiditis, te njihova kombinacija.
The wind system of claim 7, wherein the system for generating electricity also operates as motor, the generating system being actuated by a translation of the module on the rail when it operates as generator and being controlled by the smart control system when it operates as motor. 
Vjetreni sustav (1) prema zahtjevu 7, naznačen time da spomenuti sustav za proizvodnju električne energije također djeluje kao motor, da se taj generatorski sustav pokreće premještanjem spomenutog modula (5) po spomenutoj tračnici (6) kad djeluje kao generator a da njime upravlja spomenuti pametni kontrolni sustav kad djeluje kao motor.
Preparation of the Calibration Solutions: 
Broj objave europskog patenta:
Container assembly (300) according to claim 5, wherein the cover (2) comprises a protective cap for covering the membrane (28). 
Sklop (300) posude prema Zahtevu 5, gdje pokrivač (2) sadrži zaštitni poklopac za pokrivanje membrane (28).
The following benzyl amines were also prepared using procedure analogous to the described above: 
Sljedeće benzilamine također se dobije postupkom analognim onom opisanom gore:
The combined aqueous extract was washed with ether (2 x 200 mi. 
Spojeni vodeni ekstrakt se ispere sa eterom (2x200 ml.
The rim block cage according to one of the preceding claims, characterized in that the length of the flushing water distribution element (8) substantially corresponds to the length of the rim block cage (1). 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da duljina elementa za distribuciju vode za ispiranje (8) uglavnom odgovara duljini WC košarice (1).
use of an autonomous equipped underwater vehicle (100) according to any of claims 1-13; 
- < upotreba autonomnog opremljenog podvodnog vozila (100) sukladno bilo kojem od zahtjeva 1 - 13;
The compounds of the fifth aspect of this invention and the process of the fourth aspect of this invention are useful in the preparation of compounds of the first aspect of this invention. 
Spojevi petog aspekta ovog izuma i postupak četvrtog aspekta ovog izuma su korisni u pripravi spojeva prvog aspekta ovog izuma.
A combination as claimed in claim 1, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and clodronic acid, or a pharmaceutically acceptable salt thereof. 
Kombinacija prema patentnom zahtjevu 1, naznačena time da sadrži N-(3-metoksi-5-metil-pirazin-2-il)-2-(4- [1,3,4-oksadijazol-2-il)fenil)piridin-3-sulfonamid i klodronsku kiselinu, ili njihovu farmaceutski prihvatljivu sol.
The topical veterinary composition of clause 11, wherein the avermectin or milbemycin is eprinomectin, ivermectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, or moxidectin 
Topikalni veterinarski pripravak prema zahtjevu 8, naznačen time, da avermektin ili milbemicin je eprinomektin, ivermektin, selamektin, milbemektin, milbemicin D, milbemicin oksim ili moksidektin.
A vehicle according to claim 1 or 2, wherein the container includes a side door (32), the container being arranged to discharge material laterally to one side of the chassis (30) when the side door is opened to a material discharge position. 
Vozilo prema patentnom zahtjevu 1 ili 2, pri čemu spremnik ima bočna vrata (32), i podešen je za istovar tereta bočno s jedne strane okvira (30) kada su bočna vrata otvorena u položaju za istovar tereta.
The aim of the invention was to elaborate a composition and process which are suitable for the preparation of pellets in up-to-date fluidization and rotogranulation machines providing the preparation of the product fraction (that is the ratio of pellets used for further processing) in a high yield, that is in a yield of at least 75%, preferably more that 80%, and in a suitable quality. 
Cilj ovog izuma je definiranje smjese i postupka koji je pogodan za priređivanje granula u suvremenim strojevima za fluidiziranje i rotacijsko granuliranje čime se dobiva frakcija produkta (dio granula koje se rabe za daljnju obradu) s visokim prinosom, dakle s prinosom bar 75%, poželjnije većim od 80%, uz odgovarajuću kakvoću.
A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: 
1. Derivat pirimidona prikazan formulom (1), ili njegova sol, ili njegov solvat ili njegov hidrat:
A frame according to claim 9, wherein the bearing portion in which said seat is obtained has a longitudinal size that is greater than a longitudinal size of the other bearing portion. 
Okvir u skladu sa patentnim zahtjevom 11, gdje noseći dio (10) u kome navedeno sjedište (16) je dobiveno ima uzdužnu veličinu koja je veća od uzdužne veličine drugog nosećeg dijela (10).
Furthermore, the invention relates to a method for manufacturing a medicament for the prevention and/or treatment of congestive heart failure, characterised in that a solid formulation according to the invention is used. 
Čvrsta formulacija prema bilo kojem od patentnih zahtjeva 1 do 17, naznačena time, da se upotrebljava u postupku prevencije i/ili liječenja kongestivnog srčanog zastoja kod sisavca, poželjno kod psa, mačke ili glodavca.
providing a nucleic acid amplification reaction condition; 
(b) osiguravanje uvjeta za reakciju amplifikacije nukleinske kiseline;
Speed by volume of the fluidization air was kept at 60 m3/hour in the first 15 minutes of the pelletization and later at 90 m3/hour. The temperature of the fluidization air was set at 25 °C in the first part of the pelletization and at 40 °C for the drying procedure. 
Volumna brzina zraka za fluidiziranje održavana je na 60 mVsat tijekom prvih 15 minuta granuliranja i nakon toga na 90 m?/sat, Temperatura zraka za fluidiziranje održavana je na 25"C tijekom prvog dijela granuliranja te na 40"*C tijekom postupka sušenja.
The residue was chromatographed on silica gel (0% to 10% diethyl ether:cyclohexane) to give the title compound (4.14 g, 66%) as a yellow oil which was a mixture of diastereomers. 
Ostatak se kromatografira na silikagelu (0 % do 10 % dietil-eter/cikloheksan) kako bi se dobilo naslovni spoj (4,14 g, 66%) u obliku žutog ulja, koje je smjesa dijastereomera.
7 is a view of a capsule intended for use in a machine according to the present invention, the capsule being shown according to two vertical sectional planes intersecting on the axis of the capsule. 
Slika 7 je prikaz kapsule za upotrebu u stroju prema ovom izumu, gdje je kapsula prikazana po dvije ravnine okomitog presjeka koje se sijeku na osi kapsule.
adapting an ion proportion in said first leach solution, whereby a ratio between cations precipitable as phosphate compounds and phosphate ions is increased when a phosphate mole content in said first leach solution is higher than a mole amount expected to be precipitated in said step of adding a base to said first leach solution, keeping said mole ratio to be larger than 1; said step of adapting an ion proportion in said first leach solution comprises adding of at least one of ferric iron and aluminium to said first leach solution before said precipitation of phosphate compounds in said step of adding a base to said first leach solution. 
prilagođavanje (214) ionskog udjela u spomenutoj prvoj otopini za ispiranje dodavanjem (215) barem jednog od trovalentnog željeza i aluminija u spomenutu prvu otopinu za ispiranje prije spomenutog taloženja fosfatnih spojeva u spomenutom koraku dodavanja (220) baze u spomenutu prvu otopinu za ispiranje, pri čemu se povećava omjer između kationa koji se mogu istaložiti kao fosfatni spojevi i fosfatnih iona, kad je fosfatni molarni sadržaj u spomenutoj prvoj otopini za ispiranje viši nego molarna količina očekivana za taloženje u spomenutom koraku dodavanja baze u spomenutu prvu otopinu za ispiranje, održavajući spomenuti molarni omjer većim od 1.
After stirring for 5 min benzyl bromide (49.2 g, 0.29 mol) was added and the reaction was stirred for 16 h. 
Nakon miješanja tijekom 5 minuta dodan je benzil bromid (49.2 g, 0.29 mol) i reakcija je miješana tijekom 16 sati.
The present invention provides a more quickly achieving effective treatment and/or prevention of abstinence syndrome in a subject in need thereof. 
Ovaj izum pruža brže postizanje učinkovitog liječenja i/ili sprječavanja apstinencijskog sindroma kod subjekta kojemu to treba.
the pharmaceutical composition of (142), further comprising at least one additional therapeutic agent. 
Farmaceutski sastav patentnog zahtjeva 3, dalje sadrži najmanje jedan dodatni terapeutski agens.
The antibody-like binding protein of any one of claims 1, 2, 5 or 6, wherein the binding protein is bispecific and capable of binding two different antigen targets, wherein, preferably, the two different antigen targets are selected from the group consisting of IL4 and IL13, IGF1R and HER2, IGF1R and EGFR, EGFR and HER2, BK and IL13, PDL-1 and CTLA-4, CTLA4 and MHC class II, IL-12 and IL-18, IL-1a and IL-1B, TNFa and IL12/23, TNFa and IL-12p40, TNFa and IL1B, TNFa and IL-23, and IL17 and IL23. 
Protutijelu sličan vezivni protein prema bilo kojem od zahtjeva 1, 2, 5 ili 6, naznačen time da vezivni peptid je bispecifičan i može vezati dva različita antigenska cilja, pri čemu, poželjno, dva različita antigenska cilja se biraju iz skupine koju čine IL4 i IL13, IGF1R i HER2, IGF1R i EGFR, EGFR i HER2, BK i IL13, PDL-1 i CTLA-4, CTLA4 i MHC razred II, IL-12 i IL-18, IL-1a i IL-1B, TNFa i IL12/23, TNFa i IL-12p40, TNFa i IL1B, TNFa i IL-23, i IL17 i IL23.
The organic layer is washed with brine then evaporated. 
Organski sloj se ispere sa zas. otopinom NaC1 i zatim se ispari.
A solid form of a HCl salt of Compound (I-S): which is characterized by an XRPD pattern comprising peaks at approximately 13.71, 14.22, and 20.87 degrees 2θ. 
Čvrsti oblik HCl soli spoja (I-S): naznačen time što je čvrsti oblik kristalni oblik Oblika A s karakterističnim XRPD uzorkom koji ima vrhove na približno 15.09, 15.94 i 22.30 stupnjeva 2Ɵ.
Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da je u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
Inhaler according to claim 14, wherein the inhaler has a triggering device which is configured to enable or to prevent the releasing or triggering of the tensioning device depending on a tensioning state of the tensioning device. 
Inhalator prema jednom od prethodnih patentnih zahtjeva, naznačen time, što zatezni mehanizam (28) ima povratni element (47) koji je izveden za natezanje ili za pomicanje aktivacijske poluge (26) natrag u njezino stanje mirovanja.
The pharmaceutical composition according to claim 1 or 2, wherein the composition provides steady state plasma levels of 3 a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za uporabu prema patentnom zahtjevu 1, naznačen time, da sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3B-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 50 ng/ml do 250 ng/ml.
reacting the 5-aryl or 5-heteroaryl-3-hydroxy-2-carboxypyridine formed in step (C) with a compound having the formula: 
D) reakciju 5-aril ili 5-heteroaril-3-hidroksi-2-karboksipiridina formiranog u koraku (C) sa spojem formule:
A stable aqueous composition comprising a protein and polyethylene glycol, wherein the aqueous composition is free of polysorbate and wherein the polyethylene glycol is present at a concentration of 10,000 ppm or less. 
Stabilan predmetni vodeni pripravak, naznačen time, da obuhvaća protein i polioksietilen (POE) sorbitan, pri čemu je POE sorbitan prisutan u koncentraciji od otprilike 150 ppm do 10 000 ppm, te time, da spomenuti pripravak ne sadrži polisorbat.
forming a first composition comprising the trans-(+)-A9-tetrahydrocannabinol from step (b), trans-(−)-A9-tetrahydrocannabinol, and a non-polar organic solvent. 
(e) formiranje prvog sastava koji sadrži trans-(-)-A*-tetrahidrokanabinol i trans-(+)-A*-tetrahidrokanabino! iz koraka (0), te nepolarno organsko otapalo,
The reagents and reaction conditions for such procedures are well known in the chemical art. 
Reagansi i reakcijski uvjeti za takve postupke dobro su poznati u kemijskoj struci.
Method according to claim 1, characterised in that said body having cylindrical geometry (4) is made through the steps of: forming an extrusion (2) of the detergent and/or deodorant means, 
– oblikovanja ekstruzijom (2) detergentnog i/ili dezodorantnog sredstva, – rezanja komada ekstruzije kako bi se načinilo navedeno tijelo koje ima geometriju valjka (4).
Disclosed are compositions comprising (a) at least one compound selected from compounds of Formula 1, N-oxides, and salt thereof, 
Kompozicija koja sadrži (a) najmanje jedan spoj izabran od spojeva formule 1, njihovih N-oksida i soli, Q
The product was dried to a max. residue of 10-16% of water. 
Proizvod se suši do 10 do 16% vlage.
X— is a pharmaceutically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-tlouenesulfonate. 
X- je fiziološki prihvatljiv anion kojeg se bira iz skupine koju čme klorid, bromid, jodid, hidroksid, sulfat, nitrat, fosfat, acetat, trifluoracetat, fumarat, citrat, tartarat, oksalat, sukcinat, mandelat, metansulfonat i p-toluensulfonat.
an additional tank (415), connected through a three ways distributor (416), that contains clean water; this additional quantity of water can be useful in order to dilute the sprayed solution, or to alternate different steps of cleaning, with special substances and without them. 
- < dodatni spremnik (415) povezan preko trosmjernog razdjelnika (416), koji sadrži čistu vodu; ova dodatna količina vode može biti korisna radi razrjeđivanja raspršene otopine ili da zamijeni različite korake čišćenja posebnim supstancama i bez njih.
The communication method according to one of claims 1 to 3, further comprising: 
Komunikacijska metoda sukladno zahtjevu 1, naznačena time da se SRS prijenos vrši periodično.
Preferably, the outer surface of the rotary element is parallel to the inner wall surface of the vessel, e.g. the rotary element and a coaxial section of the inner wall surface of the vessel are spaced and cylindrical or conical. 
Postupak prema zahtjevu 2, naznačeno time da je cijev dio zida cirkularnog križnog presjeka nositelja koji sadrži tekući sastav 1 da se rotacijski element rotira na osovini koja je koaksijalno postavljena unutar dijela zida nositelja.
is selected from the group consisting of hydrogen, methyl, chloro, fluoro, hydroxy, methoxy, ethoxy, propoxy, carbamoyl, dimethylamino, amino, formamido, and trifluoromethyl; and 
R, je odabran iz skupine koju čine: vodik, C;-Cg alkil, C3-Cgcikloalkii, aril, supstituirani aril, heteroaril i supstituirani heteroaril, gdje su aril, heteroaril i supstituenti za aril i heteroaril prethodno definirani;
If the acoustic signal requires a current greater than 30 mA, the signal from the receiver should preferably be connected through a relay, as shown in Figure 11. 
Ukoliko zvučni signal zahtijeva struju veću od 30 mA, signal iz prijemnika treba po mogućnosti biti spojen preko releja, kao što je prikazano na Slici 11.
an increase in muscle mass or volume; 
(a) povećanjem mišićne mase ili volumena;
Therefore, by the simple method of monitoring voltage of motor 42, intelligence can be gathered about the rate of mist from nozzle 12. 
Tako se jednostavnim postupkom praćenja napona motora 42 mogu skupiti podaci o količini magle na izlazu iz brizgaljke 12.
An antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for simultaneous, concurrent, separate or sequential use in combination with a B2 agonist as defined in claim 1 or 3, for the treatment of a respiratory disease as defined in claim 7 or 8. 
Antagonist M3 muskarinskih receptora kako je definirano u zahtjevu 1 ili 2 za paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s P2 agonistom kako je definirano u patentnom zahtjevu 1 ili 3, naznačen time, da je namijenjen liječenju bolesti dišnog sustava kao što je definirano u zahtjevu 7 ili 8.
The packaging may be adapted to comprise and accommodate a memory element readable by a computer, such as a memory card. 
Pakiranje se može prilagoditi tako da obuhvaća i prihvaća memorijski element kojega može čitati kompjutor, takav element kao što je memorijska kartica.
The composition in accordance with the present invention is applied as a film or as a thin layer on the nail surface in order to prevent and/or treat specific alterations of the ungual structure, like reduced strength, onychoschizia and ungual brittleness. 
Pripravak koji se koristi u ovom izumu nanosi se kao film ili kao tanki sloj na površinu nokta kako bi se spriječile i/ili liječile specifične promjene ungualne strukture, poput smanjene snage, listanja noktiju i ungualne krhkosti.
The compound of claim 26 wherein R′ and R2 are, independently, H, halogen, methyl, or trifluoromethyl. 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da su R'iR* neovisno, H, halogen, metil ili trifluorometil.
In contrast, IL-2 does not precipitate at these SDS concentrations during SDS removal according to the invention - even as SDS decreases from 1200µg/mg (about 0.1% SDS based on 1.1 mg IL-2) down to 70µg (<0.01%), IL-2 precipitation is not seen. 
Nasuprot tome, IL-2 se ne taloži pri ovim koncentracijama SDS za vrijeme odstranjivanja SDS u skladu s izumom, čak kako se SDS smanjuje od 1200ug/mg (oko 0,1% SDS bazirano na 1,1 mg IL-2) na niže do 70ug (<0,01%), taloženje IL-2 nije zapaženo.
(a8) an antigen-binding site comprising the of H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 96, 97, and 98 (H chain CDRs of Q405), respectively; 
(a8) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 21 3 od SEQ ID NO: 96, 97 odnosno 98 (H-lanac CDR-područja od Q405);
Another aspect of the invention relates to a process for preparing a compound of Formula (Ic): 
Postupak za pripravu spoja sa formulom (Ic), RO O
A pharmaceutical composition, comprising the compound of any one of claims 1-12, or a pharmaceutically acceptable salt, or solvate thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, sadrži tvar iz bilo kojeg od patentnih zahtjeva 1-12, ili njenu farmaceutski prihvatljivu sol ili solvat i farmaceutski prihvatljivi nosač.
A method for inhibiting endothelial barrier dysfunction in an in vitro collection of endothelial cells comprising an endothelial barrier that dysfunctions or is at risk of dysfunction, said method comprising providing said collection of endothelial cells with an inhibitor of Abl-related gene (ARG) function, wherein said inhibitor is selected from: an inhibitor of tyrosine kinase activity of the protein encoded by said Abl-related gene (ARG) selected from nilotinib or a pharmaceutically acceptable salt thereof, dasatinib or a pharmaceutically acceptable salt thereof, and imatinib or a pharmaceutically acceptable salt thereof; an anti-ARG antibody that binds ARG and inhibits function; and 
Postupak za inhibiciju disfunkcije endotelne barijere u in vitro kolekciji endotelnih stanica koja sadrži endotelnu barijeru koja je u disfunkciji ili je u riziku od disfunkcije, pri čemu navedeni postupak sadrži osiguranje navedene kolekcije endotelnih stanica s inhibitorom funkcije gena povezanog s Abl (ARG), pri čemu je navedeni inhibitor odabran iz: a) inhibitora aktivnosti tirozin kinaze proteina kodiranog od strane navedenog gena povezanog s Abl (ARG) odabranog od nilotiniba ili njegove farmaceutski prihvatljive soli, dasatiniba ili njegove farmaceutski prihvatljive Soli, i imatiniba ili njegove farmaceutski prihvatljive soli; b) anti-ARG antitijela koji veže ARG i inhibira funkciju; i c) molekula nukleinske kiseline koji uzrokuje razlaganje ARG ili inhibira funkciju, transkripciju ili translaciju ARG.
FIG. 4 shows a cross-section in the longitudinal direction of the line according to FIG. 
prikazuje presjek u uzdužnom smjeru cijevi u skladu sa slikom 3.
The apparatus of claim 1 wherein the nozzle provides substantially uniform consistent spray but not atomization of the mixture. 
Sustav prema zahtjevu 1, naznačen time što mlaznica osigurava u biti ravnomjeran konzistentan mlaz ali ne i usitnjavanje mješavine.
a time-deinterleaver to time-deinterleave the data in the data symbols; 
sredstva (r709) za frekvencijsko rasplitanje podataka u analiziranom signalnom okviru;
Although not wishing to be limited by theory, it is believed that the modified ketomethylenic or thioketomethylenic side chain of the compounds of formula I leads to a lower renal toxicity compared with methotrexate. 
Iako bez želje biti ograničen teorijom, vjeruje se da modificirani ketometilenski ii tioketometilenski bočni lanac spojeva formule I vodi do niže renalne toksičnosti u usporedbi s metotreksatom.
A preferred embodiment of the present invention is represented by those combinations which comprise as component A) a compound of the formula I, wherein R1 is difluoromethyl or trifluoromethyl; Y is —CHR2— and R2 is hydrogen or C1-C6alkyl; and one component B) as described above. 
"a Klorotalonil, Epoksikonazol i Protiokonazol. Postupak prema zahtjevu 1, naznačen time, da je komponenta A) spoj sa formulom I, pri čemu R, je difluorometil ili trifluorometil; Y je -CHR>-, te R> je vodik ili C;-Csalkil.
each R2 is hydrogen or optionally substituted C1-6 aliphatic; 
je vodik ili po izboru supstituirani C1-6 alifatski;
% of increment of lag phase with respect to control (mean ± s.e.m.) 
Spoj % porasta lag faze u odnosu prema kontroli (prosjek +s.e.m.)
The peptide according to any one of the preceding claims, wherein the effective inflammatory mediator release-reducing amount of said peptide comprises a degranulation-inhibiting amount of peptide that reduces the amount of at least one inflammatory mediator released from at least one inflammatory cell from between 5 to 99% as compared to the amount released from at least one inflammatory cell in the absence of the peptide. 
Peptid za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time da stvarna količina spomenutog peptida koji smanjuje otpuštanje posrednika upale sadrži jednu količinu koja inhibira degranulaciju tog peptida koji smanjuje otpuštanje najmanje jednog posrednika upale koji se otpušta iz najmanje jedne upalne stanice za 5 do 99% u usporedbi s količinom koja bi bila otpuštena iz najmanje jedne upalne stanice da nema tog peptida.